anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention refers to novel 2-(1,2,4-triazole-1-yl)-1,3,4-thiadiazole derivatives of formula (I) having an influence on the heart and the central nervous system, furthermore pharmaceutical compositions containing the above derivatives, and a process for the preparation of the novel compounds. In formula (I) R1 represents a hydrogen atom, a C¿1-4? alkyl group or a phenyl group optionally substituted by 1 to 3 substituents selected from the group defined in the application, Z stands for a hydrogen atom or a C1-4 alkoxy group, R?0¿ means a group of the formula Alk-NR4R5 wherein Alk is a C¿1-6? straight or branched chain alkylene group, R?4 and R5¿ represent, independently, a hydrogen atom, a C¿2-6? alkenyl group, a C1-8 alkyl group optionally substituted by a substituent selected from the group defined in the application, or R?4 and R5¿ form together with the adjacent nitrogen atom and optionally with one or more further nitrogen and/or oxygen and/or sulfur atom(s) a 5- to 10-membered saturated heterocyclic group, optionally substituted, one of R?2 and R3¿ is an amino group, while the other stands for an amino group or a 5- to 10-membered saturated heterocyclic group containing one or more nitrogen and/or oxygen and/or sulfur atom(s) and being linked through its nitrogen atom, said heterocyclic group being optionally substituted or the latter one of R?2 and R3¿ means a group of formula -SR wherein R represents a C¿1-8? alkyl group, a C2-6 alkenyl group or a C2-6 alkinyl group, wherein the alkyl group is optionally substituted by a phenyl group or a halophenyl group, and optionally one or both amino group(s) is/are substituted by 1 or 2 substituent(s) selected from the group consisting of a C1-6 alkyl group, a C2-6 alkenyl group, a phenyl(C1-4 alkyl) group or a halophenyl-(C1-4 alkyl) group.
BACKGROUND: To date, the etiology and risk factors of torticollis are still poorly defined in the pediatric literature. Especially in the Emergency Department (ED) scenario, it is critical to reliably distinguish benign and transient conditions from (potentially) life-threatening disorders. This study describes the clinical characteristics of a large sample of children with torticollis. The aim of our study was to detect epidemiology, etiology and predictive variables associated with a higher risk of life-threatening conditions in acute torticollis.
METHODS: We conducted a pediatric retrospective study of acute torticollis over a 13-year period referred to the ED of a tertiary pediatric Hospital. We reported the characteristics in the overall sample and in two subgroups divided according to urgency of the underlying condition. Furthermore, we developed a multivariate model aimed at identifying the main clinical predictors of the need for urgent care.
RESULTS: 1409 patients were analyzed (median age 5.7 years, IQR 5.8). A history of trauma was present in 393 patients (27.9%). The symptom most frequently associated with torticollis were pain (83.5%). At least one pathological finding was found in 5.4 to 7.9% of patients undergoing further imaging. Hospitalization was required in 11.1% of cases (median duration 4 days). The most frequent etiologies of torticollis were postural cause (43.1%), traumatic (29.5%), and infective/inflammatory (19.1%). A longer time from onset of torticollis and the presence of headache or vomiting were strongly correlated with an underlying urgent condition, after adjusting for the other clinically and statistically significant variables in the bivariate analysis.
CONCLUSION: Our study shows that an urgent condition most commonly occur in patients presenting with history of trauma or headache, vomiting and torticollis for more than 24 h should undergo further diagnostic evaluation and short-term follow-up, restricting invasive or expensive investigations to patients with clinical suspicion of an underlying harmful condition.
The age-related decline in appetite and food intake - termed "anorexia of ageing" - is implicated in undernutrition in later life and hence provides a public health challenge for our ageing population. Eating behaviour is controlled, in part, by homeostatic mechanisms which sense nutrient status and provide feedback to appetite control regions of the brain. Such feedback signals, propagated by episodic gut hormones, are dysregulated in some older adults. The secretory responses of appetite-related gut hormones to feeding are amplified, inducing a more anorexigenic signal which is associated with reduced appetite and food intake. Such an augmented response would indicate an increase in gut sensitivity to nutrients. Consequently, this review explores the role of gastrointestinal tract nutrient sensing in age-related appetite dysregulation. We review and synthesise evidence for age-related alterations in nutrient sensing which may explain the observed hormonal dysregulation. Drawing on what is known regarding elements of nutrient sensing pathways in animal models, in other tissues of the body, and in certain models of disease, we identify potential causal mechanisms including alterations in enteroendocrine cell number and distribution, dysregulation of cell signalling pathways, and changes in the gut milieu. From identified gaps in evidence, we highlight interesting and important avenues for future research.
A preferred embodiment the present invention provides a system for extracting and concentrating active ingredients from herbs. The herbs are boiled in a suitable extraction medium, such as water or alcohol, in an extraction vessel. The extraction vessel is connected to a vacuum line that both serves to lower the pressure of the extraction vessel and to draw off herbal vapor formed in the boiling process. A vapor condenser cools the herbal vapor, forming an herbal condensate that is collected and periodically reintroduced into the extraction vessel, thereby lowering the density of the herbal liquid. After a predetermined period of time, a first portion of herbal liquid is transferred from the extraction vessel to a concentration tank, while the remainder of the herbal liquid continues to boil in the extraction vessel. In a further preferred embodiment of the present invention, the concentration tank is provided with side and bottom heating elements work together to minimize burning of the contents of the concentration tank.
Patients with metastatic melanoma patients who have failed prior anti-PD(L)1 will be enrolled. Anti-PD(L)1 therapy should be the immediate prior regimen before study entry.
Participants will receive oral doses of selexipag matrix tablets based on release profiles (IR=immediate release, F=fast release, M=medium release and S=slow release) in treatment sequence 1 (IR+F+M+S), treatment sequence 2 (F+S+IR+M), treatment sequence 3 (M+ IR+ S+F) and treatment sequence 4 (S+M+F+IR) in periods 1, 2, 3, and 4, respectively under fasted condition. A washout period of at least 7 days will be maintained between each treatment period.
Participants attend the laboratory on two or three occasions and wear accelerometers for the 10 days in between the first and second laboratory session. The first laboratory session involves urine sample collection, the completion of questionnaires, blood sample collection, acquisition of cross-sectional images of the thigh and calf, and a whole-body composition scan. The researchers will use the accelerometers at the wrist to measure time spent in moderate to vigorous physical activity, and the accelerometers at the ankle as an analogue for knee joint loading. The second laboratory session will consist of a 30-minute run on an instrumented treadmill (measures force of each step taken) whilst wearing non-invasive reflective markers, electromyography devices, and an accelerometer at the ankle. Participants are also invited to undergo optional repeated blood sampling to measure levels of markers of cartilage production and breakdown during rest and in response to a 30-minute run. If participants volunteer for the optional repeated blood sampling, they will be asked to attend a third laboratory session where blood samples will be taken at 24 hours after the run in the second laboratory session.
Sorbitol-Mannitol Irrigation is a sterile, nonpyrogenic, hypotonic, aqueous solution for urologic nonelectrolyte irrigation during transurethral surgical procedures. Each 100 mL contains sorbitol 2.70 g and mannitol 0.54 g in water for injection. The solution is nonelectrolytic and hypotonic (178 mOsmol/liter calc.); pH 5.2 (4.0 to 7.0).

The solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only for use as a single-dose irrigation. When smaller volumes are required the unused portion should be discarded.

Sorbitol-Mannitol Irrigation is a nonelectrolyte urologic irrigant.

Sorbitol, NF is chemically designated D-glucitol (C6H14O6), white powder, granules or flakes very soluble in water. It has the following structural formula:

Mannitol, USP is chemically designated D-mannitol (C6H14O6), white crystalline powder or free-flowing granules, freely soluble in water. It has the following structural formula:

Water for Injection, USP is chemically designated H20.

The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly.

The semi-rigid container is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The container requires no vapor barrier to maintain the proper drug concentration.

Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.

Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.
OBJECTIVES: I. Determine the response rate to carboplatin and paclitaxel in elderly patients with metastatic or recurrent unresectable non-small cell lung cancer. II. Determine the toxicity of this regimen in these patients. III. Determine if the hypothesized lack of social support impacts the recruitment of elderly patients into clinical trials. IV. Determine if a previously validated tool of functional status in the elderly predicts treatment related toxicity superior to that predicted by the ECOG performance status in this patient population.
Placebo taken orally within 2 hours before surgery and placebo taken orally twice daily after surgery beginning after successful extubation (day after surgery or later) until discharge or 5 days, whichever comes first. Participants will also receive standard pain management.
OBJECTIVE: To evaluate the safety study of percutaneous gastroscopic gastrostomy in patients after ventriculoperitoneal shunt.
METHODS: We conducted a retrospective analysis of neurosurgical patients who underwent VPS and PEG at our hospital between January 2012 and November 2023. Patients were divided into 2 groups: VPS group and VPS followed by PEG gruop. Patients received routine antibiotic prophylaxis before the procedure, continued for 48 hours. Follow-up included monitoring immediate complications, particularly wound infection, intracranial infection, neurologic status deterioration, and shunt dysfunction. Routine follow-up visits were conducted post-discharge.
RESULTS: In the VPS group (n = 778), the incidence of intracranial infection was 3.08%. Among patients with PEG after VPS, the time interval between procedures ranged from 13 to 685 days. The mean follow-up period was 22 (1-77) months, with no deaths or further complications.
CONCLUSION: Performing PEG more than 13 days after VPS does not significantly increase the risk of intracranial infections or PEG-associated infections, making it a relatively safe procedure.
An active substance useful in the treatment of malignant tumours is prepared by treating at 25-35 DEG  C. animal blood, serum or milk, undiluted with water, with an excess of substantially non-aqueous water-miscible solvent to precipitate protein bodies containing the active substance; separating the solvent from and drying the precipitate; and dispersing the dried precipitate in a neutral to slightly alkaline physiological common salt solution. The solvent may be absolute alcohol or acetone.  The solvent may be separated by centrifuging, the precipitated residue being evaporated in vacuo and then powdered.  The final dispersion may be treated with a solid adsorbent such as kaolin, Fuller's earth or Bolus alba, followed by centrifuging to obtain a clear elution containing the active substance.  The blood should preferably be taken from female animals during the advanced stages of pregnancy, and the milk from female animals just after parturition.  Specifications 403,269 and 682,017 are referred to.
This invention relates to the prevention and treatment of obesity in mammals, especially humans. In particular, the invention relates to novel food and beverage products, which are useful in control of obesity via the regulation of lipid and carbohydrate metabolism. The invention is applicable to both human and veterinary medicine and in animal husbandry.  According to a first aspect, the invention provides an organism, useful in food or beverage production, comprising a nucleic acid molecule, comprising a first nucleic acid segment encoding a growth hormone fragment which has the ability to modulate lipid metabolism, optionally operably linked to a second nucleic acid segment encoding an epitope tag or a heterologous fusion protein partner,  with the proviso that the first nucleic acid segment does not encode an intact, full-length mammalian growth hormone. In another aspect the invention provides a food, beverage or food additive comprising a growth hormone fragment which has the ability to modulate lipid metabolism.  In one embodiment, the invention provides a host cell, transformed with a nucleic acid molecule according to the invention. The host cell may be a microorganism used in a production of a fermented food or beverage product, or may be a cell of an edible plant, such as a fruit or vegetable, including but not limited to tomato, banana, and potato. Alternatively the host cell may be a cell of a transgenic non-human mammal, such as a cow, sheep or goat, which secretes the growth hormone fragment into its milk.
Males visit MRI twice. Once for indomethacin visit (hypoxia + hypercapnia), and once for placebo visit (hypoxia + hypercapnia). We will conduct these 2 MRI visits in a double-blind placebo controlled design. CBF measured via MRI sequences, and hemodynamics monitored for safety/research.
A pituitary gonadotropic hormone is obtained from menopausal or post-menopausal human urine by acidifying the urine to pH 4-4.5, adding thereto 0.5% by weight thereof of siliceous or diatomaceous earth and 1% by weight of kaolin and separating the solid by centrifugation after agitating for about an hour.  Thereafter, the solids are washed (using acidified water of pH about 4.5) and the active material removed therefrom by elution with 1M aqueous ammonia to give an eluate of pH 11 to 11.3.  This eluate is adjusted to pH 8.5 to give a precipitate which is removed and the pH of the supernatant is adjusted to 5-5.5 and about 2 volumes of acetone are added and the whole is left overnight.  The precipitate obtained is washed (using acetone, ethanol and ether successively), dried and taken up in 70% aqueous alcohol containing about 10% ammonium acetate, from which a precipitate is obtained by addition of ethanol containing 10% ammonium acetate. The precipitate is dissolved in 0.05M phosphate buffer (pH 7.0) and stirred with diethylaminoethyl cellulose.  The supernatant is acidified to pH 5.4 and passed through a synthetic alumino-silicate gel cation exchanger column from which the active material is subsequently eluted with 40% aqueous ethanol containing 10% ammonium acetate and precipitated by addition of 95% ethanol.  Thereafter, the active material may optionally be further purified by passing an aqueous solution thereof through a "Sephadex" (Registered Trade Mark) column and collecting the first fractions of the effluent.  The product comprises follicular stimulating hormone (FSH) and luteinizing hormone (LH) having an FSH:LH activity ratio of at least 3:1 and has a total gonadotropic activity (determined by the mouse uterus test) of above 80 mg. equivalent I.R.P. per mg.
The effectiveness of immediate-release lamotrigine as adjunctive therapy was initially established in 3 pivotal, multicenter, placebo-controlled, double-blind clinical trials in 355 adults with refractory partial-onset seizures.

The effectiveness of LAMICTAL XR as adjunctive therapy in partial-onset seizures, with or without secondary generalization, was established in a 19-week, multicenter, double-blind, placebo-controlled trial in 236 patients aged 13 years and older (approximately 93% of patients were aged 16 to 65 years). Approximately 36% were from the U.S. and approximately 64% were from other countries including Argentina, Brazil, Chile, Germany, India, Korea, Russian Federation, and Ukraine. Patients with at least 8 partial-onset seizures during an 8-week prospective baseline phase (or 4-week prospective baseline coupled with a 4-week historical baseline documented with seizure diary data) were randomized to treatment with LAMICTAL XR (n = 116) or placebo (n = 120) added to their current regimen of 1 or 2 AEDs. Approximately half of the patients were taking 2 concomitant AEDs at baseline. Target doses ranged from 200 to 500 mg/day of LAMICTAL XR based on concomitant AED (target dose = 200 mg for valproate, 300 mg for AEDs not altering plasma lamotrigine, and 500 mg for enzyme-inducing AEDs). The median partial seizure frequency per week at baseline was 2.3 for LAMICTAL XR and 2.1 for placebo.

The primary endpoint was the median percent change from baseline in partial-onset seizure frequency during the entire double-blind treatment phase. The median percent reductions in weekly partial-onset seizures were 47% in patients treated with LAMICTAL XR and 25% on placebo, a difference that was statistically significant, defined as a 2-sided P value ≤0.05.

Figure 2 presents the percentage of patients (X-axis) with a percent reduction in partial-onset seizure frequency (responder rate) from baseline through the entire treatment period at least as great as that represented on the Y-axis. The proportion of patients achieving any particular level of reduction in partial-onset seizure frequency was consistently higher for the group treated with LAMICTAL XR compared with the placebo group. For example, 44% of patients randomized to LAMICTAL XR experienced a 50% or greater reduction in partial-onset seizure frequency compared with 21% of patients randomized to placebo. 

Figure 2. Proportion of Patients by Responder Rate for LAMICTAL XR and Placebo Group (Partial-Onset Seizure Study)
PROBLEM TO BE SOLVED: To prepare a cosmetic for pack containing a perfume precursor, capable of confirming its proper pack ending period owing to sustainedly releasing scent therefrom, and enjoying new use feeling. SOLUTION: This cosmetic or pack contains 0.01-20wt.% of a perfume precursor capable of producing a perfume component on being decomposed by a hydrolase, such as a known perfume glycoside, glyceride, peptide derivative, amino acid derivative or phosphoric ester derivative, and also is formulated with 0.01-20wt.% of a hydrolase having ability to decompose the perfume precursor. The perfume involved is e.g. an alcohol-based, phenolic, carboxylic acid- based, or amine-based one. For this cosmetic, skin indigenous bacteria act on the precursor to effect releasing scent only when it is applied to the skin, thereby informing the relevant user of proper pack time. Furthermore, formulation of the hydrolase in this cosmetic enables the control of both the releasing level and time of scent, leading to higher effectiveness as an indicator of pack time.
FIELD: pharmacy. SUBSTANCE: capsule envelope of soft gelatinous capsules is made of gelatinous cords and has at least 5 wt.-% of a component that is able for migration. This component is a nonvolatile solvent that is able to mix with gelatin or form the solid solution with gelatin. The indicated component is taken among the group including tetrahydrofuryl alcohol ester, diethylene glycol monoethyl ester, 1,3-dimethyl-2-imidazolidinone, dimethylisosorbitol, polyethylene glycol and propylene glycol. Capsules have an active substance exhibiting water solubility 1% mas./vol., not above. For making soft gelatinous capsules gelatin is formed as cords followed by their cooling with a liquid, preferably - water. Obtained soft gelatinous capsules are stable at the storage for some years, they have the satisfactory solidity and retain nondeformable envelope. EFFECT: improved quality and properties of capsules. 23 cl, 1 dwg, 6 ex
Crizanlizumab is a monoclonal antibody targeting P-selectin. Crizanlizumab 5.0 mg/kg in 100 ml IV once.
Multicenter, randomized, controlled, phase 3 trial comparing the safety and efficacy of pacritinib with that of BAT in patients with thrombocytopenia and primary or secondary myelofibrosis. Approximately 300 eligible patients will be randomized in a 1:1:1 allocation to pacritinib 400 mg dosed QD, pacritinib 200 mg dosed BID, or BAT (includes any physician-selected treatment for myelofibrosis, such as approved JAK2 inhibitors administered according to package insert for patients with thrombocytopenia, and may include any treatment received before study entry). Spleen volume will be measured by MRI or CT at baseline and every 12 weeks thereafter. An independent radiology facility (IRF), blind to treatment assignments, will measure spleen volumes. Patients will also be followed for safety, Leukemia Free Survival (LFS), Overall Survival (OS), frequency of red blood cell (RBC) and platelet transfusions, and other exploratory endpoints. An Independent Data Monitoring Committee (IDMC) will evaluate the safety of pacritinib.